AstraZeneca’s Symbicort Inhalation Aerosol is going to be available for 6-12 years old children with asthma in the US, as the US Food and Drug Administration (FDA) on Wednesday granted six months of paediatric exclusivity for it.
The FDA’s approval came after testing the Inhalation Aerosol in targeted group of children with asthma. Symbicort is currently approved in the US to treat asthma in patients 12 years and older and for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) in adults.
Symbicort was first approved by the FDA in the US in July 2006 for 12+ aged patients with asthma.
DUBLIN--(BUSINESS WIRE)--The "China Inhalation Preparation Market Insight Report, 2021-2025" report has been added to ResearchAndMarkets.com's offering. In 2019, the global market size of asthma /COPD drug market exceeded USD 20 billion, and China's market size was about RMB 20 billion. Inhalation preparation, as the preferred mode of administration, has clear…
Digital Dose Inhalers Trends That Will Disrupt the Market LONDON--(BUSINESS WIRE)--#digitaldoseinhaler--According to a recent Technavio report, the digital dose inhalers market is expected to grow by USD 989.44 million during 2019-2023. Growth in the digital dose inhalers market can be attributed to many segments, one of which is the product…
First and only rescue medication recommended for US approval that has been shown to reduce severe exacerbations WILMINGTON, Del.--(BUSINESS WIRE)--The Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favorable benefit risk assessment for the use of PT027 (albuterol/budesonide)…
